Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses (CIRCA-HPV)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03739775 |
Recruitment Status :
Recruiting
First Posted : November 14, 2018
Last Update Posted : January 31, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HPV Positive Pelvic Cancer | Procedure: Blood sampling | Not Applicable |
Patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up will be included.
These patients will be followed up during 30 months (2.5 years) (if no relapse occurred before) with ctDNA detection performed at each hospital visit. At each visit, clinical, biological (squamous cell carcinoma (SCC) serum marker will be done systematically) and radiological/pathology (if any) results will be prospectively collected in the study.
For the patients who have a relapse or new HPV-induced invasive cancer before 30 months, the follow-up will be discontinued at the date of the relapse.
For the patients who will have completed their follow-up for the study (2.5 years) with no relapse or new HPV-induced invasive cancer, they will be followed up for 6 months (+ 14 days), to collect any late relapse (if any). None specific study procedure will be performed during this period.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 172 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses |
Actual Study Start Date : | January 24, 2019 |
Estimated Primary Completion Date : | June 1, 2026 |
Estimated Study Completion Date : | June 1, 2026 |
Arm | Intervention/treatment |
---|---|
Blood sampling |
Procedure: Blood sampling
Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals. |
- Sensitivity of plasma circulating tumor DNA detection as a test to detect any (local or distant) relapse in patients who have been curatively treated for HPV-induced invasive pelvic cancer (cervix, anal canal, vagina, vulva, penis). [ Time Frame: up to 36 months ]Sensitivity= % of patients with number of copies/ml of ctDNA > threshold among those who experience a relapse within 6 months (+14 days) after the blood draw.
- Specificity of plasma circulating tumor DNA detection as a test to detect any (local or distant) relapse in patients who have been curatively treated for HPV-induced invasive pelvic cancer (cervix, anal canal, vagina, vulva, penis). [ Time Frame: up to 36 months ]Specificity= % of patients with number of copies/ml of ctDNA < threshold among those who don't experience a relapse within the 6 months after the blood draw (+14 days)
- Positive predictive values of ctDNA. [ Time Frame: up to 36 months ]Positive Predictive Value= Probability of being diagnosed with a relapse within 6 months (+14 days) after positive testing (number of copies of ctDNA in the plasma > threshold).
- Negative predictive values of ctDNA. [ Time Frame: up to 36 months ]Negative Predictive Value= Probability of being relapse-free during the 6 months (+14 days) after negative testing (number of copies of ctDNA in the plasma < threshold).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
1) Patient curatively treated within the past 3 years for:
- a HPV-induced stage Ib3, Ic, II or III cervix cancer
- a HPV-induced stage II or III anal canal, vagina, vulva or penis cancer
- Patient with no evidence of any invasive tumor at inclusion (clinical and, if any, radiological exams).
- Age ≥ 18 years
- Availability of HPV genotyping of the treated cancer and/or archived tumor tissue available.
- Patient who a follow-up visit is scheduled in the including center at least twice a year.
- Patient being affiliated to the French social security.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patient presenting with active invasive tumor masses (e.g. stage IV cancer).
- Patient deprived from ability to decide on her own or placed under the authority of a tutor.
- Patient unable to have a regular follow up for geographical, social or psychological reasons.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03739775
Contact: François-Clément BIDARD, PhD | +33 (0)1 47 11 18 80 | francois-clement.bidard@curie.fr | |
Contact: Cyrine EZZILI | +33(0)1 47 11 16 57 | drci.promotion@curie.fr |
France | |
CHU de Besançon | Recruiting |
Besançon, France, 25030 | |
Contact: Christophe BORG, MD | |
Principal Investigator: Christophe BORG, MD | |
Institut Curie - Paris | Recruiting |
Paris, France, 75005 | |
Principal Investigator: Bruno BUECHER, MD | |
Hôpital Tenon | Recruiting |
Paris, France, 75020 | |
Principal Investigator: Florence HUGUET, MD | |
CHU Pontchaillou | Recruiting |
Rennes, France, 35033 | |
Principal Investigator: Astrid LIEVRE, PhD | |
Institut Curie - Saint-Cloud | Recruiting |
Saint-Cloud, France, 92210 | |
Principal Investigator: Nicolas POUGET, MD |
Principal Investigator: | François-Clément BIDARD, PhD | Institut Curie Paris |
Responsible Party: | Institut Curie |
ClinicalTrials.gov Identifier: | NCT03739775 |
Other Study ID Numbers: |
IC 2017-01 CIRCA-HPV |
First Posted: | November 14, 2018 Key Record Dates |
Last Update Posted: | January 31, 2024 |
Last Verified: | January 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Sponsor will share de-identified data sets. Documents generated under the project will be disseminated in accordance with Institut Curie policies. |
Supporting Materials: |
Statistical Analysis Plan (SAP) |
Time Frame: | Data requests can be submitted starting 9 months after last article publication and will be made accessible for up to 12 months. |
Access Criteria: | Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA). |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
HPV positive pelvic cancer Circulating tumor biomarker |
Pelvic Neoplasms Neoplasms by Site Neoplasms |